Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $17.48, but opened at $18.13. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $17.56, with a volume of 2,682 shares changing hands.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on TLX shares. Wedbush started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note on Thursday. They set an "outperform" rating and a $22.00 price objective for the company. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.
View Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 3.4%
The business has a 50 day moving average price of $16.76 and a 200-day moving average price of $16.83.
Institutional Trading of Telix Pharmaceuticals Limited American Depositary Shares
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
